Ann: Appendix 4C - quarterly, page-2

Sydney, Australia - 29 January, 2016 - Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ:
BNTCW) today lodged its Appendix 4C quarterly cash flow report for the 31 December 2015.
Operating cash outflows for the six months were AU$14.2 million and included scientific spending of
AU$7.7 million. The cash outflow included AU$2.0 million for acquisition of the preclinical ddRNAi-based
hepatitis B (HBV) therapeutic program from Biomics Biotechnologies. Research and development costs
were consistent with forecasts in the SEC F1 disclosures.
The company also incurred NASDAQ IPO costs of AU$2.0million in the half year which together with the
Biomics outgoing of AU$2.0million represents $4.0million in non-recurring outgoings. Because of these
non-recurring costs, the Company expects cash outflows will decrease in coming quarters and the
Company is committed to managing cash outflows and controlling costs. Cash at the end of the
December quarter was AU$25million.
During the quarter, the Company announced that it had entered into an agreement with Lonza Group, a
global leader in biological, cell and viral gene therapy manufacturing to develop a scalable
manufacturing process for Benitec’s ddRNAi-based products that use Adeno-Associated Virus (AAV).
In addition, Benitec presented important in vitro clinical data on the Company's hepatitis B program at
the HEP DART Conference in December, which demonstrated that BB-HB-331 can effectively suppress
multiple aspects of the hepatitis B virus (HBV) in infected human liver cells. Benitec expects to report on
in vivo hepatitis B data is CYQ2 2016.
Benitec continues an executive search for a new Chief Executive Officer and the search is progressing
well. The Company will report to the market as soon as an appointment is made.
A more comprehensive update on Benitec’s operations and financial matters will be provided in the
quarterly report to be submitted at the end of February 2016. The Company will provide quarterly
reports which will be accompanied by conference calls. These quarterly reports will be lodged with ASX​

and the NASDAQ within two months after each quarter end.